drugset / Trial / NCT01299467

A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge

NCT01299467

Phase 1 Withdrawn Pfizer
RandomizedCrossoverTriple-blind

Summary

The purpose of this study is to find out how long the effect of PF-03526299 last after it is inhaled by assessing the lung function of mild asthma patients after they have been exposed to allergen

Timeline

Start
2011-02
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-03526299 Unknown 1.396 mg Inhaled
Subject PF-03526299 Unknown 4.188 mg Inhaled

Indications